The Accelerate Arc system aims to eliminate time-intensive overnight subculture and laboratory-developed test sample preparation processes. Credit: Michal Jarmoluk from Pixabay.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Accelerate Diagnostics’ Accelerate Arc system and BC kit, which is designed for the rapid identification of microbial infections.

This automated positive blood culture sample preparation platform is designed for clinical laboratories to expedite the process of microbial identification (ID), which is crucial in the treatment of sepsis.

Related Company Profiles

View all

The Accelerate Arc system simplifies the workflow by automating the sample preparation for direct downstream microbial ID using Bruker‘s MALDI Biotyper CA System (MBT-CA System) and MBT-CA Sepsityper software extension.

It helps avoid the need for traditional overnight culture methods, allowing for quicker microbial ID results.

The system utilises the Bruker MBT-CA reference library, aiming to provide rapid ID results.

See Also:

The prompt ID and AST results can significantly improve patient outcomes, particularly in sepsis cases, and reduce both antimicrobial resistance rates and hospital costs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Accelerate Diagnostics president and CEO Jack Phillips said: “The FDA clearance of the Accelerate Arc system marks the beginning of an exciting journey in our broader innovation roadmap.

“Together with the Accelerate WAVE system, we are positioned to empower laboratories to deliver faster, more actionable results to clinicians, ultimately enhancing patient care and outcomes.”

The Accelerate Arc system also aims to replace overnight subculture and time-consuming laboratory-developed test (LDT) sample preparation methods.

With increasing legislation and enforcement regarding the use of LDTs, clinical laboratories now have the option to adopt the Accelerate Arc system as an automated, FDA-cleared alternative.

The Accelerate WAVE system is undergoing clinical trials as part of the process for submitting a 510(k) application to the FDA. The system aims to deliver average results within 4.5 hours.

In November 2023, Accelerate Diagnostics and Bruker signed a collaboration and quality agreement to validate the use of the Arc system with the MALDI Biotyper system.